Promising results for Accusite injectable gel
This article was originally published in Clinica
Interim clinical results have shown 100% success for Matrix Pharmaceutical's (US) Accusite injectable gel in treating squamous cell carcinoma skin cancers. The gel was injected in 15 patients with lesions once weekly for six weeks in a Phase II study, and after a further 16 weeks all patients were cured. The data are part of a 25-patient study which will be completed this year.